Churg Strauss Syndrome Market Size, Share & Trends Analysis Report By Diagnosis (Blood test, Imaging, Biopsy, Chest X-ray, CT Scan), By treatment (Biologics, Immunoglobulin, Vaccines, Steroid, Corticosteroid, Immunosuppressive drugs, Others), By End-User (Laboratories, Hospitals, Clinics, Therapeutic usage) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global Churg Strauss syndrome market size was valued at USD 358.3 million in 2022 and is projected to reach a value of USD 555.8 million by 2031, registering a CAGR of 5.0% during the forecast period (2023-2031). The growing demand for Churg Strauss syndrome in laboratories, hospitals, clinics, and other applications can be credited to the Churg Strauss Syndrome market share.

Churg-Strauss Syndrome (CSS), also known as eosinophilic granulomatosis with polyangiitis (EGPA), is a rare inflammatory disorder characterized by blood vessel inflammation. It is classified as systemic vasculitis, a group of illnesses characterized by inflammation of blood vessels throughout the body. CSS is primarily related to an excessive immune response and mainly affects small to medium-sized blood vessels.

Factors such as increasing incidences of Churg Strauss syndrome and other allergic responses and asthma, expanding elderly population, and increasing Churg Strauss syndrome in children will likely fuel Churg Strauss syndrome market growth during the assessment period. On the other hand, the poor reimbursement environment in many developing nations and people's lack of awareness about autoimmune disorders may impede market expansion over the forecast period.

Highlights

• Blood Tests are a significant contributor to the market by diagnosis.
• Corticosteroid is the standard treatment used in the market.
• Hospitals influenced the market by end-users.
• North America dominates the market.

Market Dynamics

Global churg strauss syndrome market drivers

Global aging population

The aging population is a global demographic trend that is characterized by a rising proportion of aged people in the total population. As people age, the prevalence of numerous health disorders, particularly autoimmune illnesses like CSS, increases. This demographic shift contributes to a shifting landscape of healthcare demands, underlining the significance of managing more prevalent diseases in older age groups. The World Health Organization (WHO) reports that the global population is aging due to decreased fertility rates and higher life expectancy. This demographic shift has increased the number and proportion of people over 60. With a growing population of senior people, efforts to identify and raise awareness regarding autoimmune disorders such as CSS may be increased. Healthcare providers may be more vigilant in spotting signs in older patients, resulting in higher diagnostic rates.

Furthermore, a study titled "The Epidemiology of Eosinophilic Granulomatosis with Polyangiitis in Olmsted County, Minnesota, 1976-2015," published in the journal Rheumatology (Oxford), examined the epidemiology of CSS. CSS was found to be most common in people aged 70 and up, according to the study. According to one study, women over 75 with TNBC have the most excellent CSS recurrence rates. Furthermore, the aging population may motivate researchers to investigate novel therapeutic strategies for CSS, considering older individuals' unique challenges and healthcare needs. This could include the development of drugs with improved safety profiles for older people. As a result, the worldwide aging population influences changes in healthcare demands and priorities, which may affect the Churg Strauss Syndrome Market trend.

Global churg strauss syndrome market restraints:

Lack of awareness

As a rare disease, Churg-Strauss Syndrome (CSS) confronts issues due to poor knowledge among healthcare professionals, patients, and the general public. This lack of information can lead to delayed or missing diagnoses, hindering patient treatment and research efforts. Without treatment, EGPA has a 5-year survival rate of roughly 25%. The 1-year survival rate with treatment is 90%, and the 5-year survival rate is 62%. According to a review published in the "Journal of Asthma and Allergy," CSS is frequently difficult to diagnose, and non-rheumatologists may lack awareness about the disease's various clinical manifestations. Patient surveys and advocacy groups, such as the Vasculitis Foundation, frequently claim that persons with CSS have difficulty obtaining an appropriate diagnosis quickly due to a lack of awareness.

As a result, limited disease awareness can lead to delayed or misdiagnosed cases, prolonging patients' suffering and perhaps affecting their long-term prognosis. Pharmaceutical companies may experience difficulty recruiting patients for clinical trials since individuals and healthcare providers may not notice CSS symptoms. Establishing tailored awareness campaigns, patient support programs, and educational initiatives can be hampered by a lack of awareness.

Global churg strauss syndrome market opportunity:

Increasing research and development

The research and development landscape for Churg-Strauss Syndrome (CSS) is changing, providing opportunities for innovation and discovering novel therapeutic methods. Understanding the etiology of Churg-Strauss Syndrome (CSS) opens the door to developing tailored medicines and providing more effective and specialized treatment choices. Clinical trials investigating using rituximab (anti-CD20 monoclonal antibody) in CSS treatment have yielded encouraging results. Rituximab, which targets B cells implicated in the autoimmune response, may be considered when conventional medications fail. JAK inhibitors, a small molecule inhibitor, are also being studied in autoimmune illnesses. While their efficacy in CSS has not yet been widely examined, continuing research in similar disorders may pave the way.

As a result, targeted medicines have the potential to provide more focused and effective CSS treatments while reducing the adverse effects associated with widespread immunosuppression. Targeted therapy development and approval can substantially impact the CSS therapeutic landscape, giving patients options for traditional immunosuppressive regimens. However, the need for more CSS makes recruiting enough people for large-scale clinical trials difficult, potentially slowing therapeutic development. Continued research, collaborations, and adaptive trial designs addressing these obstacles, on the other hand, are critical for progressing targeted medicines in the CSS Industry.

Regional Analysis

The global Churg Strauss syndrome market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North america dominates the global market

North America is the most significant global Churg Strauss syndrome market shareholder and is estimated to grow at a CAGR of 5.2% over the forecast period. The increasing number of asthma patients, changes in environmental circumstances, increased allergic reactions, and other factors are driving market expansion in this region. Furthermore, the rising prevalence of asthma in the aging population is likely to boost market expansion in this region. The critical element driving the rise of these locations is the increasing prevalence of autoimmune diseases and endocrine disorders. Rising awareness of the malignant implications of eosinophilic granulomatosis with polyangiitis and the development of contemporary therapeutics and drug approvals are boosting the Churg Strauss syndrome industry growth in these regions.

Additionally, Churg-Strauss syndrome is a rare condition that affects about 50,000 persons in the United States. In the United States, the prevalence of EGPA is estimated to be between 3-31 instances per million individuals. For example, Roche announced that the FDA has approved Rituxan® (rituximab) in combination with glucocorticoids for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients two years of age and older. GPA and MPA are rare, potentially fatal blood vessel disorders that affect tiny and medium-sized blood vessels.

Asia-Pacific is anticipated to exhibit a CAGR of 5.3% over the forecast period. According to Churg Strauss syndrome insights, Asia-Pacific is expected to be the fastest-growing market owing to the rising prevalence of immunosuppressive disease and hypereosinophilia-related concerns in developing countries and rising granulomatosis incidences. With the region's attractive reimbursement rules and policies offering tax benefits, Asia Pacific is predicted to experience significant growth during the projection period. Factors such as increasing the patient base, strengthening healthcare infrastructure, and increasing the incidence of anemia are also positively influencing the region's growth.

Furthermore, government programs supporting rare disease research, awareness campaigns, and orphan medication development can significantly impact the CSS market in the region. The National Policy for Rare Diseases (NPRD) 2021 in India includes measures for funding research and development for rare disease therapy and diagnosis. The initiative also intends to encourage local medicine discovery and production for rare diseases. The government also gives financial assistance to patients suffering from rare diseases. The financial aid has been enhanced from Rs 20 lakhs to Rs 50 lakhs per patient. This will help the region's market expand even more.

Europe is predicted to be the world's biggest market because of an increase in hay fever, increased government spending on sinus discomfort and inflammation, and an increased number of individuals consulting a doctor for allergic reaction problems.

The Middle East and Africa are predicted to have the smallest market share in the global church Strauss syndrome market due to low development, a lack of technical expertise, and inadequate medical facilities in developing nations in this region.

Segmental Analysis

The global Churg Strauss syndrome market is segmented based on diagnosis, treatment, end-user, and region.

The market is further segmented by diagnosis into Blood Tests, Imaging, and Biopsy.

Blood Test is a significant contributor to the market. Blood tests are frequently used to look for high levels of eosinophils, ANCA (anti-neutrophil cytoplasmic antibodies), and other inflammatory indicators. Monitoring these biomarkers assists doctors in confirming or ruling out CSS, monitoring disease activity, and guiding therapy recommendations. Blood tests are minimally intrusive and provide vital insights about the patient's immunological response and overall health, aiding in developing a comprehensive CSS diagnostic strategy.

Imaging is critical in diagnosing Churg-Strauss Syndrome (CSS) because it visualizes damaged organs and assesses the amount of vasculitis and tissue damage. X-rays, computed tomography (CT) scans, and magnetic resonance imaging (MRI) are all common imaging modalities. These procedures aid in detecting problems in the lungs, heart, and other afflicted organs, providing vital information for CSS diagnosis and monitoring. Imaging can help determine the degree of vasculitis, diagnose complications, and guide therapy decisions. It is an integral part of the diagnostic procedure since it contributes to a thorough understanding of the disease's influence on numerous organ systems.

The market can be further bifurcated by treatment into biologics, immunoglobulin, corticosteroid, and immunosuppressive drugs.

Corticosteroid is the standard treatment used in the market. Corticosteroids, such as prednisone, are a type of anti-inflammatory medicine that is frequently used to treat Churg-Strauss Syndrome (CSS). These medications decrease inflammation and immunological responses by mimicking the action of natural hormones generated by the adrenal glands. Corticosteroids are frequently used as first-line therapy to control acute symptoms and protect organs. Long-term usage, however, is accompanied by potential side effects that necessitate cautious control and consideration of other treatments. Despite their side effects, corticosteroids are essential in achieving remission and treating CSS symptoms, particularly during intense disease flares.

Immunoglobulin, or intravenous (IVIG), is a Churg-Strauss Syndrome (CSS) treatment involving purified antibodies from donated human blood. IVIG is a concentrated source of immunoglobulins injected intravenously and is thought to influence the immune system. Although the precise mechanism of action in CSS is unknown, IVIG is utilized to decrease inflammation and modulate the immune response. This treatment is frequently considered in situations with CSS where other therapies may be ineffective, contributing to overall illness control.

The Churg Strauss syndrome market is sub-segmented into Hospitals, Clinics, Laboratories, and Therapeutics Aspects based on end-user.

Hospitals influenced the market by end-users. Hospitals are an essential end-user segment in the Churg-Strauss Syndrome (CSS) market since they play an important role in diagnosing, treating, and caring for CSS patients. Hospitals provide comprehensive medical services to people suffering from severe or acute CSS symptoms, including emergency care, diagnostic treatments, and inpatient therapy. Specialized hospital departments, such as rheumatology and immunology units, work together to provide interdisciplinary care. Hospitals are hubs for CSS-related research, clinical trials, and advanced therapeutic intervention implementation. Their infrastructure and skills contribute to the overall ecosystem for managing CSS patients' complicated healthcare demands.

Clinics, including general and specialist outpatient institutions, are an essential end-user segment in the CSS industry. Rheumatology clinics, in particular, play a crucial role in CSS patients' continued management and follow-up care. These clinics provide regular consultations, disease activity monitoring, and treatment plan changes. Routine blood tests, imaging studies, and less complex medical procedures are best performed in the outpatient setting. Clinics provide accessible and tailored care, which helps patients with CSS maintain their long-term health. They are essential in keeping interactions between patient and patient-physician and encouraging adherence to treatment regimens.

Recent Developments

• December 2023- Grifols formed a strategic partnership with the Haier Group, raising asround USD 1.8 billion.
• January 2024- Heron Therapeutics announced a collaboration with CrossLink Life Sciences to expand marketing efforts for ZYNRELEF®, the first and only non-opioid dual-acting local anesthetic for post-operative pain.